Unknown

Dataset Information

0

A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients.


ABSTRACT: Pharmacokinetic analyses comparing generic tacrolimus preparations versus the reference drug in kidney transplant patients are lacking. A prospective, multicenter, open-label, randomized, two-period (14 days per period), two-sequence, crossover and steady-state pharmacokinetic study was undertaken to compare twice-daily generic tacrolimus (Sandoz) versus reference tacrolimus (Prograf®) in stable renal transplant patients. AUC(0-12h) and peak concentration (C(max) ) were calculated from 12 h pharmacokinetic profiles at the end of each period (days 14 and 28). Of 71 patients enrolled, 68 provided evaluable pharmacokinetic data. The ratios of geometric means were 1.02 (90% CI 97-108%, p = 0.486) for AUC(0-12h) and 1.09 (90% CI 101-118%, p = 0.057) for C(max) . Mean (SD) C(0) was 7.3(1.8) ng/mL for generic tacrolimus versus 7.0(2.1) ng/mL for reference tacrolimus based on data from days 14 and 28. Correlations between 12 h trough levels and AUC were r = 0.917 for generic tacrolimus and r = 0.887 for reference drug at day 28. These data indicate that generic tacrolimus (Sandoz) has a similar pharmacokinetic profile to the reference drug and is bioequivalent in kidney transplant recipients according to US Food and Drug Administration and European Medicines Agency guidelines.

SUBMITTER: Alloway RR 

PROVIDER: S-EPMC3472020 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients.

Alloway R R RR   Sadaka B B   Trofe-Clark J J   Wiland A A   Bloom R D RD  

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20120703 10


Pharmacokinetic analyses comparing generic tacrolimus preparations versus the reference drug in kidney transplant patients are lacking. A prospective, multicenter, open-label, randomized, two-period (14 days per period), two-sequence, crossover and steady-state pharmacokinetic study was undertaken to compare twice-daily generic tacrolimus (Sandoz) versus reference tacrolimus (Prograf®) in stable renal transplant patients. AUC(0-12h) and peak concentration (C(max) ) were calculated from 12 h pha  ...[more]

Similar Datasets

| S-EPMC4527535 | biostudies-literature
| S-EPMC10726046 | biostudies-literature
| S-EPMC6538151 | biostudies-literature
| S-EPMC4909584 | biostudies-literature
| S-EPMC4657844 | biostudies-literature
| S-EPMC8280658 | biostudies-literature
| S-EPMC9283366 | biostudies-literature
| S-EPMC8432116 | biostudies-literature
| S-EPMC6422729 | biostudies-literature
| S-EPMC4834594 | biostudies-literature